A study published just this week concluded that adding Keytruda to the standard chemotherapy treatment plan of adults with lung cancer slashed the odds that they would die in half.
In another recent trial, doctors found that treating patients with Keytruda before surgery greatly increased their odds of survival and added years to their lives, stopping the spread of cancer and directly targeting the cancerous cells. It is also used as a treatment option for malignant melanoma.
“I have never seen progress move so fast... The results today are really a paradigm shift. They will mean more lung cancer patients getting immunotherapy up front,” Dr. Dr. Roy Herbst, a lung cancer specialist at Yale Cancer Center who was not involved in the studies told NBC.
Read More...